Results of a phase 4 trial of Tacrobell® in liver transplantation patients

A multicenter study in South Korea

Young-Dong Yu, Sung Gyu Lee, Jae Won Joh, Choon Hyuck Kwon, Dong Gu Kim, Kyung Suk Suh, Nam Jun Lee, Shin Hwang, Chul Soo Ahn, Ki Hun Kim, Deok Bog Moon, Tae Yong Ha, Gi Won Song, Dong Hwan Jung

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/Aims: This 26-week pilot study was performed in de novo liver transplant recipients to evaluate the efficacy of tacrobell capsule as an immunosuppressant drug after living donor liver transplant patients by determining the rate of acute cellular rejection after its use and evaluating its safety after transplantation. Methodology: From October 2005 to July 2007, 57 patients from four major medical centers in Seoul, South Korea were enrolled in the study. This open-label, non-comparative, multicenter pilot study lasted 26 weeks and assigned patients to receive tacrobell and corticosteroid after liver transplantation. Tacrobell (0.05mg/kg/day, bid) and methylprednisolone were injected either on the day of the operation or on postoperative day one. A retrospective matched control group consisting of living donor liver transplant recipients at one center (Asan medical center) was used for comparison. Results: The rate of acute cellular rejection with tacrobell after 26 weeks of administration was 0.0% (95% CI, 0.0%-6.27%), which was below our hypothesized 36%. The most common drug-related adverse events included endocrine/nutritional disorders followed by gastrointestinal and hepatobiliary disorders. No patients died during the study period. The side effect profile of this drug was no different than other tacrolimus based immunosuppressants. Conclusions: Although our study was based on a low risk population and had a short-term follow up, we conclude that tacrobell, as a generic tacrolimus, can be considered safe and effective in liver transplant patients.

Original languageEnglish
Pages (from-to)357-363
Number of pages7
JournalHepato-Gastroenterology
Volume59
Issue number114
DOIs
Publication statusPublished - 2012 Mar 1
Externally publishedYes

Fingerprint

Republic of Korea
Liver Transplantation
Multicenter Studies
Living Donors
Liver
Tacrolimus
Immunosuppressive Agents
Drug-Related Side Effects and Adverse Reactions
Nutrition Disorders
Transplants
Methylprednisolone
Capsules
Adrenal Cortex Hormones
Research Design
Transplantation
Safety
Control Groups
Pharmaceutical Preparations
Population

Keywords

  • Acute rejection
  • Liver transplantation
  • Tacrobell

ASJC Scopus subject areas

  • Medicine(all)
  • Hepatology
  • Gastroenterology

Cite this

Results of a phase 4 trial of Tacrobell® in liver transplantation patients : A multicenter study in South Korea. / Yu, Young-Dong; Lee, Sung Gyu; Joh, Jae Won; Kwon, Choon Hyuck; Kim, Dong Gu; Suh, Kyung Suk; Lee, Nam Jun; Hwang, Shin; Ahn, Chul Soo; Kim, Ki Hun; Moon, Deok Bog; Ha, Tae Yong; Song, Gi Won; Jung, Dong Hwan.

In: Hepato-Gastroenterology, Vol. 59, No. 114, 01.03.2012, p. 357-363.

Research output: Contribution to journalArticle

Yu, Y-D, Lee, SG, Joh, JW, Kwon, CH, Kim, DG, Suh, KS, Lee, NJ, Hwang, S, Ahn, CS, Kim, KH, Moon, DB, Ha, TY, Song, GW & Jung, DH 2012, 'Results of a phase 4 trial of Tacrobell® in liver transplantation patients: A multicenter study in South Korea', Hepato-Gastroenterology, vol. 59, no. 114, pp. 357-363. https://doi.org/10.5754/hge11472
Yu, Young-Dong ; Lee, Sung Gyu ; Joh, Jae Won ; Kwon, Choon Hyuck ; Kim, Dong Gu ; Suh, Kyung Suk ; Lee, Nam Jun ; Hwang, Shin ; Ahn, Chul Soo ; Kim, Ki Hun ; Moon, Deok Bog ; Ha, Tae Yong ; Song, Gi Won ; Jung, Dong Hwan. / Results of a phase 4 trial of Tacrobell® in liver transplantation patients : A multicenter study in South Korea. In: Hepato-Gastroenterology. 2012 ; Vol. 59, No. 114. pp. 357-363.
@article{6a5800f69c3d41eb842a9b80c40a7c82,
title = "Results of a phase 4 trial of Tacrobell{\circledR} in liver transplantation patients: A multicenter study in South Korea",
abstract = "Background/Aims: This 26-week pilot study was performed in de novo liver transplant recipients to evaluate the efficacy of tacrobell capsule as an immunosuppressant drug after living donor liver transplant patients by determining the rate of acute cellular rejection after its use and evaluating its safety after transplantation. Methodology: From October 2005 to July 2007, 57 patients from four major medical centers in Seoul, South Korea were enrolled in the study. This open-label, non-comparative, multicenter pilot study lasted 26 weeks and assigned patients to receive tacrobell and corticosteroid after liver transplantation. Tacrobell (0.05mg/kg/day, bid) and methylprednisolone were injected either on the day of the operation or on postoperative day one. A retrospective matched control group consisting of living donor liver transplant recipients at one center (Asan medical center) was used for comparison. Results: The rate of acute cellular rejection with tacrobell after 26 weeks of administration was 0.0{\%} (95{\%} CI, 0.0{\%}-6.27{\%}), which was below our hypothesized 36{\%}. The most common drug-related adverse events included endocrine/nutritional disorders followed by gastrointestinal and hepatobiliary disorders. No patients died during the study period. The side effect profile of this drug was no different than other tacrolimus based immunosuppressants. Conclusions: Although our study was based on a low risk population and had a short-term follow up, we conclude that tacrobell, as a generic tacrolimus, can be considered safe and effective in liver transplant patients.",
keywords = "Acute rejection, Liver transplantation, Tacrobell",
author = "Young-Dong Yu and Lee, {Sung Gyu} and Joh, {Jae Won} and Kwon, {Choon Hyuck} and Kim, {Dong Gu} and Suh, {Kyung Suk} and Lee, {Nam Jun} and Shin Hwang and Ahn, {Chul Soo} and Kim, {Ki Hun} and Moon, {Deok Bog} and Ha, {Tae Yong} and Song, {Gi Won} and Jung, {Dong Hwan}",
year = "2012",
month = "3",
day = "1",
doi = "10.5754/hge11472",
language = "English",
volume = "59",
pages = "357--363",
journal = "Hepato-Gastroenterology",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "114",

}

TY - JOUR

T1 - Results of a phase 4 trial of Tacrobell® in liver transplantation patients

T2 - A multicenter study in South Korea

AU - Yu, Young-Dong

AU - Lee, Sung Gyu

AU - Joh, Jae Won

AU - Kwon, Choon Hyuck

AU - Kim, Dong Gu

AU - Suh, Kyung Suk

AU - Lee, Nam Jun

AU - Hwang, Shin

AU - Ahn, Chul Soo

AU - Kim, Ki Hun

AU - Moon, Deok Bog

AU - Ha, Tae Yong

AU - Song, Gi Won

AU - Jung, Dong Hwan

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Background/Aims: This 26-week pilot study was performed in de novo liver transplant recipients to evaluate the efficacy of tacrobell capsule as an immunosuppressant drug after living donor liver transplant patients by determining the rate of acute cellular rejection after its use and evaluating its safety after transplantation. Methodology: From October 2005 to July 2007, 57 patients from four major medical centers in Seoul, South Korea were enrolled in the study. This open-label, non-comparative, multicenter pilot study lasted 26 weeks and assigned patients to receive tacrobell and corticosteroid after liver transplantation. Tacrobell (0.05mg/kg/day, bid) and methylprednisolone were injected either on the day of the operation or on postoperative day one. A retrospective matched control group consisting of living donor liver transplant recipients at one center (Asan medical center) was used for comparison. Results: The rate of acute cellular rejection with tacrobell after 26 weeks of administration was 0.0% (95% CI, 0.0%-6.27%), which was below our hypothesized 36%. The most common drug-related adverse events included endocrine/nutritional disorders followed by gastrointestinal and hepatobiliary disorders. No patients died during the study period. The side effect profile of this drug was no different than other tacrolimus based immunosuppressants. Conclusions: Although our study was based on a low risk population and had a short-term follow up, we conclude that tacrobell, as a generic tacrolimus, can be considered safe and effective in liver transplant patients.

AB - Background/Aims: This 26-week pilot study was performed in de novo liver transplant recipients to evaluate the efficacy of tacrobell capsule as an immunosuppressant drug after living donor liver transplant patients by determining the rate of acute cellular rejection after its use and evaluating its safety after transplantation. Methodology: From October 2005 to July 2007, 57 patients from four major medical centers in Seoul, South Korea were enrolled in the study. This open-label, non-comparative, multicenter pilot study lasted 26 weeks and assigned patients to receive tacrobell and corticosteroid after liver transplantation. Tacrobell (0.05mg/kg/day, bid) and methylprednisolone were injected either on the day of the operation or on postoperative day one. A retrospective matched control group consisting of living donor liver transplant recipients at one center (Asan medical center) was used for comparison. Results: The rate of acute cellular rejection with tacrobell after 26 weeks of administration was 0.0% (95% CI, 0.0%-6.27%), which was below our hypothesized 36%. The most common drug-related adverse events included endocrine/nutritional disorders followed by gastrointestinal and hepatobiliary disorders. No patients died during the study period. The side effect profile of this drug was no different than other tacrolimus based immunosuppressants. Conclusions: Although our study was based on a low risk population and had a short-term follow up, we conclude that tacrobell, as a generic tacrolimus, can be considered safe and effective in liver transplant patients.

KW - Acute rejection

KW - Liver transplantation

KW - Tacrobell

UR - http://www.scopus.com/inward/record.url?scp=84860590402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860590402&partnerID=8YFLogxK

U2 - 10.5754/hge11472

DO - 10.5754/hge11472

M3 - Article

VL - 59

SP - 357

EP - 363

JO - Hepato-Gastroenterology

JF - Hepato-Gastroenterology

SN - 0172-6390

IS - 114

ER -